RxDoctor Payments Data

Abigail Cline, MD

Dermatology · Bronx, NYNPI 1639606536

Payments from drug & device makers

$1,572in general payments, 2019–2025

Across 37 payments — averaging $42.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$861
  • Johnson & Johnson$287
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$199
  • Janssen Scientific Affairs, LLC$125
  • Regeneron Healthcare Solutions, Inc.$52
  • Incyte Corporation$27
  • plus $22 from 1 others

What the payments were for

  • Speaking & faculty fees$25016%
  • Food & beverage$1,22778%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,572 in reported general payments places this provider in the 40th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$6,081
Medicare patients
51
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$380,768
Cosentyx Sensoready (2 Pens)Secukinumab16$113,790
OpzeluraRuxolitinib Phosphate17$47,835
Dupixent PenDupilumab13$45,265
Tacrolimus37$9,387
Clobetasol Propionate110$9,006
Fluocinonide89$5,822
Tretinoin36$3,850
Ketoconazole80$2,220
Ammonium Lactate94$1,904
Halobetasol Propionate16$1,091
Clindamycin Phosphate25$979
Triamcinolone Acetonide103$789
Hydrocortisone49$245
Mometasone Furoate12$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$27$47,83517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,151 dermatology providers in New York.

Other dermatology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →